GlassScriptPhysician profile
Jason Palmer Mader
NPI 1508132960
$13,190.76
in general payments reported to CMS, 2019-2025
33 companies · $3,409 in 2025
The $3,409 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $676 · 2021: $912 · 2022: $2,575 · 2023: $1,741 · 2024: $3,123 · 2025: $3,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,304 · Consulting Fee: $1,500 · Travel and Lodging: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,304.32 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $468.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,091.94 | 2019-2025 | Indigo System, Penumbra System |
| Zoll Circulation INC | $1,805.21 | 2022-2024 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,169.99 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $1,129.76 | 2020-2025 | General - Therapies, Avvigo Guidance System, Wolverine Coronary Cutting Balloon |
| Shockwave Medical, INC | $1,118.74 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $882.07 | 2020-2022 | |
| Abbott Laboratories | $762.91 | 2021-2025 | Cardiomems, Amplatzer Talisman, Pressurewire |
| Astrazeneca Pharmaceuticals LP | $702.82 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Abiomed | $491.76 | 2023-2025 | Impella |
| Medtronic Vascular, INC. | $307.79 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $280.04 | 2021-2022 | |
| Terumo Medical Corporation | $263.42 | 2021-2025 | Metacross Otw |
| Amgen INC. | $230.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $217.55 | 2022-2025 | |
| Medtronic, INC. | $216.75 | 2022-2024 | Hawkone, In.Pact Admiral, Onyx Frontier |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $188.09 | 2019-2025 | Kengreal |
| E.R. Squibb & Sons, L.L.C. | $187.94 | 2023-2024 | Camzyos, Eliquis |
| Stryker Corporation | $178.18 | 2025 | Flowtriever |
| Janssen Scientific Affairs, LLC | $174.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.09 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $124.98 | 2022 | |
| Impulse Dynamics (USA) INC. | $112.40 | 2025 | Optimizer |
| Lantheus Medical Imaging, INC. | $106.54 | 2023 | Definity |
| Kestra Medical Technology Services, INC. | $65.48 | 2024-2025 | Assure Wcd |
| Heartflow, INC. | $52.56 | 2023 | Ffrct |
| Inspire Medical Systems, INC. | $43.99 | 2023 | Inspire |
| Endologix LLC | $43.85 | 2025 | Torus Stent Graft System, Endocross Device |
| Pfizer INC. | $28.62 | 2019-2024 | |
| Philips North America LLC | $20.02 | 2021 | |
| Cardiva Medical, INC. | $17.15 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Cardiovascular Systems INC. | $16.52 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Bard Peripheral Vascular, INC. | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Mader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.